Company / Gross Margin
Charles River Laboratories Gross Margin History
FY2016-FY2019 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Gross Margin
11.4%
FY2019
5-year range
-
FY2016-FY2019
Trend
+42.3%
vs FY2018
Sector context
#94 of 96
Health Care
What the data says
Among 96 Health Care companies, Charles River Laboratories is in the bottom 2% for gross margin. Declined from 38.5% to 11.4% over the past 2 years.
Based on SEC 10-K filings.
11.4% in FY2019 with a 3-year CAGR of +3.0%.
Declined from 38.5% to 11.4% over the past 2 years.
Health Care sector context is included.
Gross Margin over time
Growth rates
- 3-Year Change
- +3.0pp
- 5-Year Change
- -
- 10-Year Change
- -
Sector benchmark
Bottom 2% in Health CareTop 98% of 96This company 11.4% Sector average 53.6%
▼
-78.7% below sector average
Key checks
Key Insights
- In FY2019, gross margin increased 42.3% year-over-year.
- Currently 42.2pp below the Health Care sector average.
Company context
Key Data Points
- Altman Z-Score 1.10 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Gross MarginValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | - | - |
| FY2024 | - | - |
| FY2023 | - | - |
| FY2022 | - | - |
| FY2021 | - | - |
| FY2020 | - | - |
| FY2019 | 11.4% | +42.3% |
| FY2018 | 8.0% | -79.2% |
| FY2017 | 38.5% | +360.2% |
| FY2016 | 8.4% | -18.5% |
As of FY2019 · SEC 10-K · Updated Jul 4, 2026